Oxymetazoline as a predictor of turbinate reduction surgery outcomes: Objective support from a prospective, single‐blinded, computational fluid dynamics study
International Forum of Allergy & Rhinology · 2024
DOI: 10.1002/alr.23422 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2024. Verfasst von Zachary T Root und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology - Head & Neck Surgery, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Turbinates, Oxymetazoline, Nasal Decongestants, Nasal Obstruction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
A patient's subjective response to topical nasal decongestant is often used to screen for turbinate reduction surgery suitability. However, this anecdotal strategy has not been objectively and quantitatively evaluated.
Methods
Prospective, longitudinal, and single‐blinded cohort study employing computational fluid dynamic modeling based on computed tomography scans at baseline, 30 min postoxymetazoline, and 2 months postsurgery on 11 patients with chronic turbinate hypertrophy.
Results
Nasal obstruction symptom evaluation (NOSE) and visual analogue scale (VAS) obstruction scores significantly improved from baseline to postoxymetazoline and again to postsurgery (NOSE: 71.82 ± 14.19 to 42.27 ± 25.26 to 22.27 ± 21.04; VAS: 6.09 ± 2.41 to 4.14 ± 2.20 to 2.08 ± 1.56; each interaction p < 0.05), with significant correlation between the latter two states ( r ∼0.37–0.69, p < 0.05). Oxymetazoline had a broader anatomical impact throughout inferior and middle turbinates than surgery (many p < 0.05); however, the improvement in regional airflow is similar (most p > 0.05) and predominantly surrounding the inferior turbinate. Strong postoxymetazoline to postsurgery correlations were observed in decreased nasal resistance ( r = 0.79, p < 0.05), increased regional airflow rates ( r = ‐0.47 to −0.55, p < 0.05) and regional air/mucosa shear force and heat flux ( r = 0.43 to 0.58, p < 0.05); however, only increasing peak heat flux significantly correlated to symptom score improvement (NOSE: r = 0.48, p < 0.05).
Conclusion
We present the first objective evidence that the “topical decongestant test” can help predict turbinate reduction surgery outcomes. The predictive effect is driven by similar improvementin regional airflow that leading to improved air/mucosa stimulations (peak heat flux) rather than through reduced nasal resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology - Head & Neck Surgery, The Ohio State University, Columbus, Ohio, USA.
ORCID-Profile: Zachary T Root, Zhenxing Wu, Kai Zhao
Zitieren
APA
Root, Z. T., Wu, Z., Lepley, T. J., Schneller, A. R., Chapman, R. J., Formanek, V. L., Kelly, K. M., Otto, B. A., & Zhao, K. (2024). Oxymetazoline as a predictor of turbinate reduction surgery outcomes: Objective support from a prospective, single‐blinded, computational fluid dynamics study. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23422
Vancouver
Root ZT, Wu Z, Lepley TJ, Schneller AR, Chapman RJ, Formanek VL, et al. Oxymetazoline as a predictor of turbinate reduction surgery outcomes: Objective support from a prospective, single‐blinded, computational fluid dynamics study. International Forum of Allergy & Rhinology. 2024. doi:10.1002/alr.23422
BibTeX
@article{Root2024,
author = {Root, Zachary T and Wu, Zhenxing and Lepley, Thomas J and Schneller, Aspen R and Chapman, Robbie J and Formanek, Veronica L and Kelly, Kathleen M and Otto, Bradley A and Zhao, Kai},
title = {Oxymetazoline as a predictor of turbinate reduction surgery outcomes: Objective support from a prospective, single‐blinded, computational fluid dynamics study},
journal = {International Forum of Allergy & Rhinology},
year = {2024},
doi = {10.1002/alr.23422}
}
EUVIMED